Open fetal surgery for myelomeningocele
Center for Fetal Diagnosis and Treatment, Children's Hospital of Philadelphia, Philadelphia, PA, USA. Prenatal Diagnosis
(Impact Factor: 3.27).
07/2011; 31(7):689-94. DOI: 10.1002/pd.2805
Despite efforts at prevention through the use of preconception folic acid, spina bifida remains one of the most common congenital anomalies of the central nervous system that is compatible with life. It is, however, associated with a significant degree of lifelong morbidity. The development of open fetal surgery for myelomeningocele (MMC) has been a long process but one that serves as a model for how new procedures and technologies need to be properly evaluated before being brought into mainstream medical practice. Even so, risks and benefits need to be evaluated for each patient. The currently available studies have been carried out on a highly selected patient population where the fetal findings provided the maximum opportunity for benefit from prenatal closure of the MMC defect. There is the potential that as the surgery becomes more widely available, pressure will be brought to bear to perform surgery in cases where the likelihood for benefit is decreased and yet the risks are not. The only way to duplicate the results of the current studies is to follow the methodology and criteria that were used in the studies. This will mean that not every fetus with an MMC will be a candidate for in utero surgery. The balance of risk to benefit will continue to evolve as further technological advances are evaluated and more follow-up information is obtained.
Figures in this publication
Available from: fetalmedicine.com
- "The inadequacy of the research done to date has dawned and with it we are beginning to see a more scientific approach to the development of fetal therapy with randomised trials being established to determine the optimum management for twin–twin transfusion syndrome (Chalouhi et al., 2011) and in utero repair of meningomyelocele (Bebbington et al., 2011). Gradually, we are gaining information on the natural history of some conditions to enable better case selection (Gucciardo et al., 2011) and developing better standards upon which to assess the severity of disease (Cannie et al., 2011). "
Prenatal Diagnosis 07/2011; 31(7):619-20. DOI:10.1002/pd.2809 · 3.27 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Fetal myelomeningocele closure (fMMC) was demonstrated in a randomized, prospective clinical trial to improve outcomes for children diagnosed prenatally. Complex care of the maternal/fetal dyad undergoing fetal surgery requires a well-coordinated multidisciplinary team. Nurses in many roles are essential members of the team that cares for these women across the continuum. In this article we discuss the care of the woman, fetus, and family from initial contact through the discharge of the neonate.
Journal of Obstetric Gynecologic & Neonatal Nursing 04/2012; 41(3):447-54. DOI:10.1111/j.1552-6909.2012.01357.x · 1.02 Impact Factor
Available from: Carlo Valerio Bellieni
[Show abstract] [Hide abstract]
ABSTRACT: In humans, painful stimuli can arrive to the brain at 20-22 weeks of gestation. Therefore several researchers have devoted their efforts to study fetal analgesia during prenatal surgery, and during painful procedures in premature babies. Aim of this paper is to gather from scientific literature the available data on the signals that the human fetus and newborns produce, and that can be interpreted as signals of pain. Several signs can be interpreted as signals of pain. We will describe them in the text. In infants, these signs can be combined to create specific and sensible pain assessment tools, called pain scales, used to rate the level of pain.
The AAPS Journal 04/2012; 14(3):456-61. DOI:10.1208/s12248-012-9354-5 · 3.80 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.